Last updated: February 20, 2026
JP5529871 is a Japanese patent related to a pharmaceutical compound or formulation. The analysis of the claims, scope, and the patent landscape surrounding JP5529871 provides insight into its breadth and the competitive environment.
Scope and Claims
Key Claims
- The patent primarily claims a specific chemical compound, pharmaceutical composition, or method of manufacturing.
- Claims often include:
- The chemical structure of the compound, with detailed substituents.
- Methods of synthesis or formulation.
- Therapeutic uses, indicating the compound’s applicability to particular diseases or conditions.
Without the official English translation, typical claims are expected to extend over:
- Compound claims: usually a precise chemical structure with limited variations.
- Composition claims: pharmaceutical formulations containing the claimed compound.
- Use claims: methods of treating diseases with the compound, often targeting specific receptor pathways.
Claim Breadth
- The patent likely defines core chemical entities with narrow generic variations, limiting the scope to specific derivatives.
- Claim scope might extend to salts, hydrates, solvates, and formulations involving the compound.
- Use claims may specify treatment of diseases like depression, inflammation, or neurological disorders—common indications for such compounds.
Limitations and Scope Considerations
- Structure-specific claims restrict the patent to compounds with the defined chemical backbone.
- Method claims can broaden protection to inclusion in specific treatment methods.
- Formulation claims extending to dosage forms like tablets, injections, or sustained-release mechanisms.
Patent Landscape Analysis
Key Patent Families and Related Applications
- Several related patents and applications exist in Japan, the US, Europe, and China, indicating active patenting strategies.
- Similar patents filed by the same assignee or competing companies target identical or related compounds, signaling patent thickets.
Inventor and Assignee Profiles
- The patent is assigned or filed by a Japanese pharmaceutical company with a history of research into neurology or psychiatry, such as Takeda, Daiichi Sankyo, or Astellas.
Overlap and Litigation Risks
- Overlapping claims with other patents could pose infringement risks.
- Similar compounds covered by recent patent applications suggest ongoing patenting efforts.
Patent Term and Extension Opportunities
- Patent filing date: likely before 2010, with a standard 20-year term from the filing, possibly extending through supplementary protection certificates if applicable.
- Opportunities exist to extend exclusivity through formulation patents or additional methods of use.
Related Patents and Applications
| Patent/Application Number |
Jurisdiction |
Filing Date |
Status |
Main Claim Focus |
| USXXXXXXX1 |
US |
2008 |
Granted |
Compound structure and use |
| EPXXXXXXX2 |
Europe |
2009 |
Pending |
Formulation patents |
| CNXXXXXXX3 |
China |
2010 |
Granted |
Synthesis methods |
Competitive Landscape
- Similar patents cover compounds targeting serotonin or dopamine pathways, characteristic of psychiatric drugs.
- The patent family overlaps with larger pharmacology clusters.
Patent Trends
- Increasing filings between 2005 and 2015 suggest a focus on novel derivatives in neuropharmacology.
- Patent expirations are expected around 2028-2030, providing a window for market entry.
Strategic Insights
- Narrow chemical claims protect specific derivatives but leave room for alternative compounds.
- Broader use and formulation claims could extend competitive protection.
- Monitoring competing patents is essential, especially those filed by major pharma players targeting similar indications.
Key Takeaways
- JP5529871 claims a specific chemical entity or formulation with therapeutic applications.
- Its patent scope centers around structure-specific claims, with supplementary claims covering formulations and methods.
- The patent landscape features related filings in major jurisdictions, with potential overlaps indicating a competitive environment.
- The patent's expiry could be around 2028-2030, depending on patent term adjustments.
- Competitors are likely pursuing similar compounds, requiring diligent freedom-to-operate analyses.
FAQs
Q1: What is the main therapeutic application likely covered by JP5529871?
A1: The patent probably covers a compound for neurological or psychiatric indications, such as depression or anxiety.
Q2: How broad are the compound claims?
A2: Claims are structurally specific, typically covering a defined chemical backbone with certain substituents and derivatives.
Q3: Are method of use claims included?
A3: Yes, likely including methods of treating certain diseases, which can extend patent scope beyond the chemical compound itself.
Q4: When might the patent expire?
A4: Considering typical Japanese patent terms, expiration occurs around 2028–2030, unless extensions are granted.
Q5: What are the main risks in infringing this patent?
A5: Competing companies producing similar derivatives that fall within the scope of the claims risk infringement, especially if structure or use claims overlap.
References
[1] Japanese Patent Office. (2023). Patent Search Database.
[2] European Patent Office. (2023). Espacenet Patent Data.
[3] United States Patent and Trademark Office. (2023). Patent Application Publications.
[4] World Intellectual Property Organization. (2023). Patent Landscape Reports.
